|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
clothiapine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity |
ISO |
Quetiapine Fumarate results in decreased activity of ABCB1 protein |
CTD |
PMID:16810505 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Quetiapine Fumarate inhibits the reaction [APP protein modified form affects the activity of CAT protein]; Quetiapine Fumarate inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:15948179 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Quetiapine Fumarate results in increased expression of BAX protein |
CTD |
PMID:16462815 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Quetiapine Fumarate results in increased expression of BDNF protein |
CTD |
PMID:17442489 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Quetiapine Fumarate inhibits the reaction [APP protein modified form affects the activity of CAT protein] |
CTD |
PMID:15948179 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
ISO |
Quetiapine Fumarate results in decreased expression of CNR1 protein |
CTD |
PMID:31220554 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
ISO |
Quetiapine Fumarate results in increased expression of CNR2 protein |
CTD |
PMID:31220554 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Carbamazepine promotes the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate]; CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate] |
CTD |
PMID:16390352 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein] |
CTD |
PMID:15716360 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [Ketanserin binds to HTR2A protein] |
CTD |
PMID:16314884 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Quetiapine Fumarate inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Quetiapine Fumarate results in decreased activity of KCNH2 protein |
CTD |
PMID:21158687 PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases metabolic processing |
ISO |
Quetiapine Fumarate results in decreased metabolism of MAP1LC3B protein |
CTD |
PMID:31220554 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [Cuprizone results in decreased activity of MBP protein] |
CTD |
PMID:18938062 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]; AM 1241 inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; AM 1241 inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]; AM 281 inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; AM 281 inhibits the reaction [Quetiapine Fumarate results in increased phosphorylation of MLKL protein]; Quetiapine Fumarate results in increased expression of and affects the localization of MLKL protein; Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein; Rimonabant inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein] |
CTD |
PMID:31220554 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity affects oxidation |
ISO |
Quetiapine Fumarate inhibits the reaction [[MPO protein results in increased metabolism of chlorodimedone] which results in increased abundance of Hypochlorous Acid]; Quetiapine Fumarate inhibits the reaction [MPO protein results in increased abundance of Hypochlorous Acid] Quetiapine Fumarate results in decreased activity of MPO protein MPO protein affects the oxidation of Quetiapine Fumarate |
CTD |
PMID:35575633 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Ndufv2 |
NADH:ubiquinone oxidoreductase core subunit V2 |
increases expression |
EXP |
Quetiapine Fumarate results in increased expression of NDUFV2 mRNA |
CTD |
PMID:19441803 |
|
NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Quetiapine Fumarate results in decreased expression of NGFR mRNA |
CTD |
PMID:12111809 PMID:16513140 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Prl |
prolactin |
decreases expression increases secretion |
ISO |
Quetiapine Fumarate results in decreased expression of PRL protein Quetiapine Fumarate results in increased secretion of PRL protein |
CTD |
PMID:16379509 PMID:18063941 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions increases expression |
ISO |
AM 281 inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK1 protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK1 protein] |
CTD |
PMID:31220554 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions increases expression |
ISO |
Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK3 protein] |
CTD |
PMID:31220554 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:30465787 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
ISO EXP |
Quetiapine Fumarate inhibits the reaction [Cuprizone results in decreased activity of SOD1 protein] Quetiapine Fumarate results in increased expression of SOD1 mRNA Quetiapine Fumarate inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA] |
CTD |
PMID:12111809 PMID:12752374 PMID:18938062 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
tianeptine results in increased expression of ABCC2 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
tianeptine results in increased expression of ABCG5 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
tianeptine results in increased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO |
tianeptine results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:27089845 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
tianeptine inhibits the reaction [Indomethacin results in increased activity of CAT protein] |
CTD |
PMID:19497431 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
EXP |
tianeptine results in increased expression of CNR2 protein |
CTD |
PMID:28866072 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
EXP |
tianeptine results in decreased expression of DRD2 mRNA |
CTD |
PMID:11981225 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
tianeptine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:27089845 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
tianeptine inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:19497431 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
increases activity |
ISO |
tianeptine results in increased activity of OPRM1 protein |
CTD |
PMID:32734307 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
tianeptine results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
ISO |
tianeptine binds to and results in decreased activity of SLC6A4 protein |
CTD |
PMID:16272152 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
ISO |
tianeptine results in increased expression of SREBF1 mRNA |
CTD |
PMID:27089845 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|